Home

Eli Lilly (LLY)

722.57
+3.18 (0.44%)
NYSE · Last Trade: May 29th, 6:32 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close719.39
Open719.23
Bid720.55
Ask721.75
Day's Range716.96 - 727.33
52 Week Range677.09 - 972.53
Volume2,785,539
Market Cap-
PE Ratio (TTM)-
EPS (TTM)-
Dividend & Yield6.000 (0.83%)
1 Month Average Volume5,091,992

Chart

About Eli Lilly (LLY)

Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More

News & Press Releases

Novo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli Lillyinvestors.com
Eli Lilly is rapidly encroaching on Novo Nordisk's yearslong lead in GLP-1 drugs. Can Novo hold its tentpole position?
Via Investor's Business Daily · May 29, 2025
Veru's Enobosarm Shows Muscle In Wegovy Combo Trialbenzinga.com
Via Benzinga · May 28, 2025
Novo Nordisk's 52% Plunge: Is the Company Fumbling Its Leadership in the $150 Billion Weight Loss Market?fool.com
Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels.
Via The Motley Fool · May 28, 2025
P/E Ratio Insights for Eli Lillybenzinga.com
Via Benzinga · May 27, 2025
Eli Lilly's May Meltdown Is In History Books — Could June Seasonality Bring A Rebound?benzinga.com
Eli Lilly stock down 19% in May, on track for worst month since 2009. But June historically brings better fortune, with 67% chance of closing higher.
Via Benzinga · May 27, 2025
Smart Money Is Betting Big In LLY Optionsbenzinga.com
Via Benzinga · May 27, 2025
Breaking The Pain Barrier: Lilly's Acquisition Of SiteOne Aims For Opioid Alternativesbenzinga.com
Eli Lilly to acquire SiteOne Therapeutics in a deal worth up to $1 billion, advancing the development of a potential non-opioid treatment for chronic pain.
Via Benzinga · May 27, 2025
The Vanguard S&P 500 ETF: Is It Still a Core Portfolio Holding?fool.com
Via The Motley Fool · May 27, 2025
10 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · May 27, 2025
Xiaomi Reports Record Revenue, Profit In Q1 Led By Smartphone, EV Sales: Retail Stays Optimisticstocktwits.com
Adjusted net profit jumped 64.5% YoY to hit a record high of RMB10.7 billion during the quarter.
Via Stocktwits · May 27, 2025
Why Novo Nordisk Stock Just Poppedfool.com
President Trump has good news for Novo Nordisk investors, and more may be on the way.
Via The Motley Fool · May 27, 2025
Eli Lilly To Acquire SiteOne Therapeutics For Up To $1B To Advance Pain Management Pipeline: But Retail’s Unconvincedstocktwits.com
The $1 billion is inclusive of an upfront payment and subsequent payments upon achievement of certain regulatory and commercial milestones.
Via Stocktwits · May 27, 2025
$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Todaybenzinga.com
Via Benzinga · May 27, 2025
Jim Cramer Says Rocket Is A 'Very Fine' Company, Recommends Buying This Health Care Stockbenzinga.com
Via Benzinga · May 27, 2025
Here's How the Pharmaceutical Import Tariffs Could Affect Eli Lillyfool.com
Via The Motley Fool · May 27, 2025
Prediction: These 2 Stocks Will Beat the Market in the Next Decadefool.com
Via The Motley Fool · May 27, 2025
1 Brilliant Vanguard Index Fund to Buy Before It Soars Nearly 160%, According to a Wall Street Analystfool.com
Via The Motley Fool · May 26, 2025
2 Momentum Stocks with Impressive Fundamentals and 1 to Avoid
Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or even a loyal Reddit fanbase.
Via StockStory · May 26, 2025
Value Investing Is Not Dead - It Just Got Smarterbenzinga.com
Via Benzinga · May 23, 2025
3 Trades Members of Congress Are Making Right Now
Knowing what Congressional leaders are buying can give investors insight into future legislation that could benefit these companies
Via MarketBeat · May 23, 2025
Investing for the Long Term: 1 Unstoppable Vanguard ETF to Buy and Hold Foreverfool.com
Via The Motley Fool · May 23, 2025
2 Growth Stocks to Own for Decades and 1 to Steer Clear Of
Growth is oxygen. But when it evaporates, the consequences can be extreme - ask anyone who bought Cisco in the Dot-Com Bubble (Nvidia?) or newer investors who lived through the 2020 to 2022 COVID cycle.
Via StockStory · May 23, 2025
5 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · May 22, 2025
Hims & Hers Stock Drops After Evernorth Announces Cheaper Pricing For Weight-Loss Drugs: Retail’s Dullstocktwits.com
Truist noted on Thursday that the $200/month price point is "highly attractive compared to other price points in the market," including Hims & Hers' compounded Semaglutide, Wegovy, and Liraglutide subscription programs.
Via Stocktwits · May 22, 2025
Better Weight Loss Stock: Amgen or Viking Therapeutics?fool.com
Via The Motley Fool · May 22, 2025